US Patent 7247300 Therapeutic use of soluble CD39L3
Patent 7247300 was granted and assigned to APT Therapeutics on July, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Ridong Chen0
Soon S. Jeong0
Timothy A. Mitsky0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+290 characters)
Article
Patent abstract
The present invention provides soluble forms of CD39L3 polypeptides and compositions, and methods useful inhibiting platelet activation and recruitment for the treatment and prevention of thrombotic disorders in mammals administered with soluble forms of CD39L3 polypeptides.
Edits on 16 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07247300 Therapeutic use of soluble CD39L3 US Patent 7247300 Therapeutic use of soluble CD39L3
Infobox
Patent Number
072473000
Patent Number
72473000
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 5 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072473000
Date of Patent
July 24, 2007
0Patent Application Number
107037800
Date Filed
November 7, 2003
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 22 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07247300 Therapeutic use of soluble CD39L3
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07247300
Date of patent
July 24, 2007
Patent application number
10703780
Date Filed
November 7, 2003
Patent primary examiner
Find more entities like US Patent 7247300 Therapeutic use of soluble CD39L3
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.